Translational Medicine
Open Access
ISSN: 2161-1025
ISSN: 2161-1025
Siri Muppidi
Cancer prevalence and deaths are high in developing nations, wherever resources for cancer control are inadequate. About one-quarter of cancers in resource-limited countries are infection related, and molecular tests can capitalize on this relationship by recognizing germane pathogen genomes and human gene variations to distinguish those at highest risk for progression to cancer, to classify lesions, to predict effective therapy, and to monitor tumour burden over time. Prime cases are human papillomavirus in cervical neoplasia, Helicobacter pylori and Epstein-Barr infection in gastric adenocarcinoma and lymphoma, and hepatitis B or C virus in hepatocellular cancer. Research is underway to engineer devices that overcome social, financial, and technical barriers restricting viable laboratory support. Extra challenges incorporate an educated workforce, infrastructure for quality metrics and record keeping, and funds to sustain molecular test services. The combination of well-designed interfacing, novel and vigorous electrochemical innovation, and telemedicine devices will promote adoption by frontline providers. Quick turnaround is crucial for surmounting loss to follow-up, although increased utilize of cell phones, even in rural regions, improves choices for patient education and engagement. Links to a broadband network facilitate discussion and centralized capacity of restorative information. Molecular technology appears guarantee to address crevices in health care through quick, user-friendly, and cost-effective devices reflecting clinical priorities in resource-poor regions.
Published Date: 2020-11-10; Received Date: 2020-10-26